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Rukshar K Gobarani, Nicholas A Zwar, Grant Russell, Michael J Abramson, Billie Bonevski, 
Anne E Holland, Eldho Paul, Narelle S Cox, Sally Wilson and Johnson George
Smoking cessation intervention in Australian 
general practice:
a secondary analysis of a cluster randomised controlled trial
INTRODUCTION
Smoking is the primary risk factor for the 
development of many chronic conditions, 
including chronic obstructive pulmonary 
disease (COPD). Despite the progressive 
nature of COPD and the negative impacts on 
an individual’s quality of life, approximately 
40% of people with COPD continue to smoke, 
and often find it more difficult to quit than 
other smokers.1,2
Given their high degree of contact with 
the population, GPs are well placed to assist 
in smoking cessation.3 Despite this, a study 
conducted across 30 urban and rural general 
practice clinics in Australia reported that GPs 
provided smoking-related advice to only 55% 
of smokers who were ready to change their 
smoking behaviours.4 
A number of barriers have been reported 
by GPs that limit their ability to routinely 
provide smoking cessation support.5 These 
range from practitioner-related barriers, 
such as ‘forgetting to discuss smoking’ and 
‘lack of training and skills’, to more structural 
barriers, such as a ‘lack of time’.5 Thus, 
new strategies need to be explored in order 
to target all smokers within the general 
practice setting. One such strategy may be 
to incorporate pharmacist collaboration in 
the provision of smoking cessation support in 
this setting. Current evidence suggests that 
smoking cessation interventions delivered 
by pharmacists are effective at improving 
the rates of abstinence.6 However, the 
effectiveness of such interventions when 
integrated within an Australian general 
practice setting has not been evaluated.
RADICALS — Review of airway dysfunction 
and interdisciplinary community-based care 
of adult long-term smokers — was a two-
arm, cluster randomised controlled trial 
that implemented an interdisciplinary model 
of care involving GPs and other practice 
staff, pharmacists, and physiotherapists in 
Australian general practices, and evaluated 
its effectiveness on health-related quality of 
life (HRQoL) at 6 months.7 A total of 1050 
participants were recruited for the RADICALS 
trial, which included 690 current smokers, 
350 ex-smokers, and 10 never-smokers;8 272 
Abstract
Background
GPs have limited capacity to routinely provide 
smoking cessation support. New strategies are 
needed to reach all smokers within this setting.
Aim
To evaluate the effect of a pharmacist-coordinated 
interdisciplinary smoking cessation intervention 
delivered in Australian general practice.
Design and setting
Secondary analysis of a cluster randomised 
controlled trial (RCT) conducted in 41 Australian 
general practices. 
Method
In all, 690 current smokers were included in 
this study: 373 from intervention clinics (n = 21) 
and 317 from control clinics (n = 18). A total of 
166 current smokers had spirometry-confirmed 
chronic obstructive pulmonary disease (COPD). 
In the intervention clinics, trained pharmacists 
provided smoking cessation support plus 
Quitline referral. Control clinics provided usual 
care plus Quitline referral. Those with COPD 
in the intervention group (n = 84) were referred 
for home medicines review (HMR) and home-
based pulmonary rehabilitation (HomeBase), 
which included further smoking cessation 
support. Outcomes included carbon monoxide 
(CO)-validated smoking abstinence, self-
reported use of smoking cessation aids, and 
differences between groups in readiness-to-quit 
score at 6 months.
Results
Intention-to-treat analysis showed similar 
CO-validated abstinence rates at 6 months 
in the intervention (4.0%) and control clinics 
(3.5%). No differences were observed in 
readiness-to-quit scores between groups at 
6 months. CO-validated abstinence rates were 
similar in those who completed HMR and at 
least six sessions of HomeBase to those with 
COPD in usual care.
Conclusion
A pharmacist-coordinated interdisciplinary 
smoking cessation intervention when integrated 
in a general practice setting had no advantages 
over usual care. Further research is needed 
to evaluate the effect of HMR and home-
based pulmonary rehabilitation on smoking 
abstinence in smokers with COPD. 
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had spirometry confirmed COPD at baseline.8 
The main outcomes of the trial were changes 
in St George’s Respiratory Questionnaire 
(SGRQ) score, COPD Assessment Test 
(CAT) score, dyspnoea score, smoking 
abstinence, and lung function.8 The effect 
of the RADICALS interdisciplinary primary 
care-based model for COPD (n = 272) has 
been evaluated and the findings for these 
outcomes have been presented elsewhere.8 
The effect of the RADICALS intervention on 
smoking abstinence and other smoking-
related outcomes among all current smokers 
involved in the trial (n = 690) has not been 
previously reported.8 If found to be effective, 
such a model could be a feasible approach 
to providing cessation services within the 
community. 
The aim of this secondary analysis was to 
evaluate the effectiveness of a pharmacist-
coordinated intervention on smoking 
abstinence among smokers aged ≥40 years, 
and to examine the effects of the intervention 
on readiness to quit and the use of cessation 
aids.
METHOD
Design and study population
RADICALS was conducted in Melbourne 
general practices between March 2015 and 
January 2018.7 The RADICALS study protocol 
and baseline findings have been described 
in detail elsewhere.7,9 Briefly, group or solo 
GP clinics in Melbourne with ≥1000 patients 
on their databases were approached. Upon 
obtaining signed agreement, practices were 
block randomised (block sizes of four and six) 
to the control or intervention groups.8 Eligible 
participants were those aged ≥40 years 
who had visited the clinic at least twice in 
the previous year and self-reported being 
a current or an ex-smoker with a smoking 
history of ≥10 pack years, or those who had 
a documented diagnosis of COPD on clinic 
records or were being managed with COPD-
specific medications.7 At each clinic, trained 
research assistants identified potential 
participants based on the eligibility criteria 
and contacted them via mail or telephone.7 
Upon obtaining written informed consent, 
participants were interviewed at the practice. 
For the present analysis, the authors 
excluded participants who were ex-smokers 
(n = 350) or never smokers (n = 10). Only 
those who reported being a current smoker 
in baseline interviews were included in this 
analysis (n = 690).
Study arms
All smokers in the RADICALS trial, regardless 
of their diagnosis, were eligible for the 
smoking cessation intervention. Copies of 
the Supporting Smoking Cessation: a Guide 
For Health Professionals10 publication were 
provided to clinic staff in both groups. 
Intervention group. GPs in the intervention 
clinics continued to provide routine care to 
their patients. Smoking cessation support 
at intervention clinics was coordinated by a 
pharmacist appointed at each site as part 
of the study. The pharmacist contacted the 
GP for initiating any prescription medications 
for smoking cessation. Pharmacists had 
smoking cessation training through QUIT 
Victoria (a government funded agency that 
promotes smoking cessation and offers a 
range of information, services, and tools for 
smokers and health professionals), which 
included an online training module consisting 
of educational videos and other materials.11,12
Pharmacists provided smoking cessation 
support guided by a treatment algorithm 
developed by Thomas et al.13 Smoking 
cessation support was tailored to the 
individual’s readiness to quit and consisted 
of a counselling session during baseline 
interviews, telephone follow-up calls 
at 1 week and 1 month from the initial 
consultation, and a referral to Quitline, a free 
telephone support and counselling service 
to help people quit smoking. Telephone 
follow-ups re-emphasised the importance 
of quitting. Over-the-counter and/or 
prescription medications (through the GP) for 
smoking cessation were also recommended, 
if appropriate.
Current smokers with spirometry-
confirmed COPD were referred for a home 
medicines review (HMR) and home-based 
pulmonary rehabilitation (HomeBase). 
Performed by an accredited consultant 
pharmacist, the HMR consisted of an 
interview with the participants in their homes 
(about 1.5 hours' duration) to assess and 
enhance medication use. The pharmacist 
How this fits in 
Interdisciplinary models for smoking 
cessation are beneficial, and highlight 
that different treatment approaches 
across a range of healthcare settings are 
complementary. Interventions involving 
pharmacists are effective in assisting 
smokers to quit, but no studies have 
evaluated the effectiveness of such 
interventions within general practices. 
This study evaluated the effect of such 
strategies on quit rates, which, if proven to 
be effective, could be a feasible approach 
to delivering smoking cessation services 
within a general practice setting.
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also provided further individualised 
smoking cessation support, including 
recommendations for pharmacotherapy, if 
relevant. A report including recommendations 
for optimising medication use (especially for 
COPD and to assist smoking cessation), and 
any issues or concerns identified during the 
interview, was forwarded by the pharmacist 
to the individual’s GP following completion of 
the HMR.8 
The 8-week HomeBase programme 
was conducted by a trained physiotherapist 
and consisted of one home visit and seven 
once-weekly follow-up telephone calls.14 
The programme comprised individually 
prescribed, home-based aerobic and 
resistance exercise training and telephone 
calls based on motivational interviewing that 
included discussions on smoking behaviour 
and quitting using the 5As approach (ask, 
advise, assess, assist, arrange).10
Control group. GPs in control clinics 
continued to provide routine care to their 
patients. In addition, participants were 
referred to Quitline.
Follow-up
Participants were followed up at 6 months by 
research assistants blind to group allocation. 
Follow-up was conducted face-to-face or 
via telephone, and involved the completion 
of a structured questionnaire and a carbon 
monoxide (CO) breath test in participants 
who self-reported abstinence at the 6-month 
follow-up.
Outcomes
The primary outcome of this analysis 
was carbon monoxide (CO)-verified 7-day 
point prevalence smoking abstinence at 
6 months from baseline. Self-reported 
7-day point prevalence abstinence (that is, 
smoking not even a puff in the previous 
7 days) was assessed at the 6-month follow-
up. Participants who self-reported 7-day 
point prevalence abstinence were requested 
to undergo a CO breath test. Exhaled CO 
levels were measured using a handheld piCO 
Smokerlyzer (Bedfont Scientific, Maidstone, 
UK). CO levels ≤6 parts per million (ppm) 
confirmed abstinence.15 Participants with 
missing follow-up data or whose self-
reported abstinence was not biochemically 
validated were considered to be smokers in 
accordance with the Russell Standard.16
Secondary outcomes included:
• the proportion of smokers who self-
reported the use of smoking cessation aids 
or alternative therapies over the 6-month 
period;
• changes within groups (from baseline to 
6 months) and differences between groups 
at 6 months in readiness-to-quit score; 
and
• CO-validated 7-day point prevalence 
abstinence at 6 months from baseline in 
smokers with COPD.
Data were collected from participants 
using validated tools at baseline and at 
6 months. This included the readiness-
to-quit scale (to assess motivation to quit 
smoking along a continuum).10 In addition, 
self-reported utilisation of smoking cessation 
pharmacotherapies or alternative products 
(for example, electronic cigarettes) was 
explored at the 6-month follow-up.
Statistical analysis
Baseline demographic characteristics were 
summarised using counts and proportions, 
means and standard deviations (SD), or 
medians and interquartile ranges (IQR), 
depending on data distribution. The primary 
analysis was performed according to the 
intention-to-treat (ITT) principle. Logistic 
regression models were used to examine 
the effectiveness of the intervention, with 
results reported as odds ratios (OR) and 
95% confidence intervals (CI). Changes in 
readiness-to-quit score were compared 
between treatment groups using linear 
regression, with results reported as mean 
difference and 95% CIs. All regression 
analyses were adjusted for clustering by 
practice. A subgroup analysis of smokers 
with COPD was undertaken to analyse the 
efficacy of the HMR and the HomeBase 
components of the RADICALS intervention. 
Statistical significance was set at a two-sided 
P-value of 0.05. Analyses were conducted 
using Statistical Package for Social Sciences 
(SPSS) (version 25.0) and Stata version 14.0).
RESULTS
A total of 690 current smokers were recruited 
(317 from 18 control clinics, and 373 from 
21 intervention clinics); 166 had spirometry-
confirmed COPD (82 in the control group, and 
84 in the intervention group) (Figure 1).
The intervention and control groups were 
similar at baseline (Table 1). The majority of 
the 166 current smokers with COPD (126, 
76.0%) had mild COPD, defined as forced 
expiratory volume in 1 second, 60% ≤FEV1 
<80% predicted.8
Primary outcome
At the 6-month follow-up, there was 
no significant difference in CO-verified 
abstinence rates between the control and 
intervention groups (OR 1.17, 95% CI = 0.52 
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to 2.64). In the ITT analysis, the CO-verified 
7-day point prevalence abstinence rates were 
3.5% and 4.0% in the control and intervention 
groups, respectively. CO-validated abstinence 
rates remained unchanged when a higher 
CO cut-off of <10 ppm was used (3.8% and 
4.3% in the control and intervention groups, 
respectively), (data not shown).
Baseline readiness (OR 1.27, 95% CI = 1.06 
to 1.52) and confidence in quitting (OR 1.42, 
95% CI = 1.18 to 1.71) were significantly 
associated with CO-verified 7-day point 
prevalence abstinence at 6 months. No 
significant differences in CO-verified 
abstinence rates were seen after adjusting 
for baseline readiness and confidence in 
quitting (adjusted OR 1.04, 95% CI = 0.44 to 
2.47), (data not shown).
Secondary outcomes
Only 177 (25.7%) of all current smokers 
(n = 690) reported using a smoking cessation 
aid or alternative therapy (such as electronic 
cigarettes, acupuncture, or hypnotherapy) to 
assist them in quitting over the 6-month 
period. No significant differences were 
observed in the proportions of smokers 
who reported using a smoking cessation 
aid or alternative therapy during the follow-
up period between the control (24.3%) and 
intervention groups (28.7%) (P = 0.5), (data 
not shown).
Over the 6-month period, nicotine 
replacement therapy (NRT) was the most 
commonly used smoking cessation aid by 
smokers in both groups (n = 118, 66.7%) 
followed by varenicline (n = 40, 22.6%). Of 
the participants who used NRT, seven also 
used varenicline during the follow up period. 
Among those who achieved CO-validated 
abstinence at 6 months, 50% reported the 
use of smoking cessation aids over that 
time period. Varenicline was the agent most 
commonly used by quitters, followed by NRT.
Use of smoking cessation aids and 
alternative therapies by smokers with COPD 
(n = 166) was low, with only 42 (25.3%) 
reporting the use of such aids over the 
Figure 1. Flow diagram of the smoking cessation 
component of the RADICALS intervention. 
COPD = chronic obstructive pulmonary disease. 
HMR = home medicines review. HomeBase = home-
based pulmonary rehabilitation. ITT = intention-to-
treat. N = number of clinics. n = number of participants. 
RADICALS = Review of airway dysfunction and 
interdisciplinary community-based care of adult long-
term smokers.
Clinics randomised (N = 41)
Clinics allocated to usual-care group (N = 20)
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participants (N = 18)
Participants consented and completed
baseline data collection (n = 417)
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Usual care
Included in ITT analysis (n = 317)
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(n = 1)
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6-month period. Only 11 (26.2%) of those 
completing the HMR component (n = 42) and 
seven (25.9%) of those completing at least 
six sessions of HomeBase (n = 27) reported 
using a smoking cessation aid or alternative 
therapy over the follow-up period.
No significant differences were observed 
between the control and intervention groups 
at 6 months in readiness-to-quit scores 
(Supplementary Table S1). Improvements 
seen within groups from baseline to 
6 months in readiness-to-quit score did not 
reach statistical significance. 
In smokers with COPD, the CO-verified 
abstinence rate at 6 months was lower in 
the control group (n = 3, 3.7%) compared 
with those who completed HMR and at least 
six sessions of HomeBase (n = 2, 9.1%) 
(P = 0.29), (data not shown). The low uptake 
of the HMR and HomeBase components of 
the intervention limited any further statistical 




A pharmacist-coordinated smoking cessation 
intervention delivered in collaboration 
with other health professionals in general 
practice did not influence abstinence rates 
at 6 months. No differences were noted 
between groups in readiness-to-quit 
scores at 6 months. Additionally, 6-month 
abstinence rates in smokers with COPD were 
higher in those who completed HMR and at 
least six sessions of HomeBase compared 
with those who received usual care plus 
Quitline referral. However, due to the low 
uptake of the intervention components, 
further research is needed to confirm these 
findings. 
Strengths and limitations
The main strength of this study was its 
pragmatic nature and the number of clinics 
and GPs involved in the study. Clinics differed 
in size and socioeconomic status of patients, 
increasing the generalisability of the findings. 
The cluster randomised design minimised 
the risk of contamination. The interventions 
tested were readily available and could be 
implemented in general practice. Outcome 
assessments were performed by research 
assistants blinded to group allocation, 
minimising the risk of bias.
Although smoking cessation training 
was offered to all pharmacists, individual 
differences may have impacted the nature of 
support offered to smokers. The dissemination 
of smoking cessation guidelines to GPs in the 
control arm may have prompted changes in 
the support offered to smokers presenting at 
these clinics, which would not have otherwise 
occurred. Additionally, some clinics in the 
control arm were already delivering smoking 
cessation services to their patients before 
the trial. Quitline referral was offered to both 
control and intervention groups. This may 
have contributed to the lack of a difference 
between the two arms of the study, as 
evidence indicates that such telephone-based 
smoking cessation services are effective at 
increasing quit rates.17 Moreover, smokers 
were recruited into the trial when they were 
not actively seeking medical help. This 
recruitment strategy may have impacted on 
the authors’ findings, as anti-smoking advice 
is more effective when linked to the patient’s 
Table 1. Baseline demographics and clinical characteristics of 
current smokers in the usual-care and intervention groups 
 Control Intervention Total  
 (n = 317) (n = 373) (n = 690)
Male, n (%) 175 (55.2) 198 (53.1) 373 (54.1)
Age, years (mean ± SD) 56.0 ± 8.7 57.7 ± 10.1 56.9 ± 9.5
Born in Australia,a n (%) 224 (70.7) 259 (69.4) 483 (70.0)
Highest education,b n (%)
Less than high school 13 (4.1) 25 (6.7) 38 (5.5)
High school 159 (50.2) 147 (39.4) 306 (44.3)
Technical and further education (TAFE) 72 (22.7) 107 (28.7) 179 (25.9)
University/postgraduate 73 (23.0) 89 (23.9) 162 (23.5)
Employment status,a n (%)
Employed 149 (47.0) 165 (44.2) 314 (45.5)
Retired/pensioner 96 (30.3) 125 (33.5) 221 (32.5)
Unemployed/home duties/student/disabled 72 (22.7) 80 (21.4) 152 (22.0)
Average household income in AUD,c n (%)
<30 000 94 (29.7) 153 (41.0) 247 (35.8)
30 000—59 999 57 (18.0) 71 (19.0) 128 (18.6)
≥60 000 85 (26.8) 101 (27.0) 186 (27.0)
Did not want to disclose 73 (23.0) 42 (11.3) 115 (16.7)
Smoking start age, yearsd (mean ± SD) 17.0 ± 5.3 16.6 ± 4.7 16.8 ± 5.0
Heaviness of smoking index,e n (%)
Low nicotine dependence (score 0–2) 126 (40.4) 144 (38.6) 270 (39.1)
Moderate nicotine dependence (score 3–4) 147 (46.4) 171 (45.8) 318 (46.1)
High nicotine dependence (score 5–6) 39 (12.3) 54 (14.5) 93 (13.5)
HADS-Af (mean ± SD) 9.8 ± 2.8 9.9 ± 2.6 9.8 ± 2.7
HADS-Df (mean ± SD) 12.4 ± 1.7 12.6 ± 1.9 12.5 ± 1.8
Quit smoking for at least 1 day in the last 12 months,d n (%) 176 (55.5) 187 (50.1) 363 (52.6)
Used smoking cessation aid in past quit attempts,g n (%) 140 (44.2) 165 (44.2) 305 (44.2)
Current readiness to quit, median (IQR)h 5 (4–8) 5 (4–7) 5 (4–7)
Current motivation to quit, median (IQR)i 6 (3–8) 6 (4–8) 6 (4–8)
Current confidence to quit, median (IQR)j 5 (2–6) 5 (3–7) 5 (3–7)
Spirometry-confirmed COPD, n (%) 82 (25.9) 84 (22.5) 166 (24.1)
aMissing data, n = 3. bMissing data, n = 5. cMissing data, n = 14; Australian annual pension rate for singles is ~AUD 
24 000. dMissing data, n = 4. eMissing data, n = 9. fMissing data, n = 11. gMissing data, n = 8. hMissing data, n = 9. 
iMissing data, n = 6. jMissing data, n = 7. AUD = Australian dollars. COPD = chronic obstructive pulmonary disease. 
HADS-A = hospital anxiety and depression scale score for anxiety. HADS-D = hospital anxiety and depression scale 
score for depression. IQR = interquartile range. SD = standard deviation.
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presenting complaint.18 Low intensity of 
the smoking cessation intervention, limited 
follow-up, and poor uptake of smoking 
cessation pharmacotherapy may also explain 
the low abstinence rates observed.
Comparison with existing literature
The results of this study were not consistent 
with those of Chen et al, who evaluated the 
efficacy of individual counselling in smokers 
with or without COPD.19 The current study 
reported a significant difference in abstinence 
rates at 6 months between the intervention 
and usual-care groups (23.4% versus 10.4%, 
respectively, P = 0.007).19 However, the 
majority of the COPD patients in the study 
by Chen et al were recruited from pulmonary 
outpatient clinics and thus represent a 
population with potentially more severe 
symptoms and a stronger motivation to quit 
than the present study participants.8 When 
Chen et al removed smokers with COPD from 
the analysis, the effect of the intervention was 
no longer statistically significant.19 
The current findings are consistent with 
those of Zwar et al, who assessed the 
effectiveness of an interdisciplinary team of 
general practice nurses and GPs developing 
and implementing an evidence-based 
disease management plan for patients 
newly diagnosed with COPD.20 Practice 
nurses and GPs in the intervention clinics 
received educational material and training 
on various aspects of COPD disease 
management and smoking cessation.20 
At 6 months, no significant difference in 
self-reported abstinence rates were noted 
between the intervention (22.2%) and control 
groups (26.0%) (OR 0.92, 95% CI = 0.44 to 
1.91).20 Similar to the findings of the present 
study, the low uptake of the intervention 
by participants in the intervention group 
may have contributed to the lack of effect 
observed by Zwar et al.20
Evidence from a qualitative study shows 
that most smokers view motivation to quit 
as a factor that is essential for successful 
smoking abstinence.21 A majority of smokers 
believe that the process needs to be initiated 
by themselves, and is independent of 
any external motivational factors such as 
discussions with GPs or family members.21 
The modest level of motivation to quit 
among the current cohort may be a possible 
explanation for the lack of effect on abstinence 
noted in this study. 
The use of smoking cessation 
pharmacotherapies and non-
pharmacological aids reported in the current 
study was low, but similar to that observed 
previously.22,23 Although varenicline is one of 
the most effective pharmacological agents 
for smoking cessation, its use was relatively 
low in this study.24–26
The present study was pragmatic in 
nature and the intervention provided was less 
intensive than in other studies.19 The reported 
abstinence rate of 4.0% in the intervention 
group in this study is similar to that observed 
in spontaneous quitters (3–5%).27 A Cochrane 
review has suggested that increasing the 
intensity of behavioural support for people 
making a quit attempt with the aid of 
pharmacotherapy increased the proportion 
who achieve long-term abstinence (risk ratio 
[RR] 1.29, 95% CI = 1.09 to 1.53).28 Another 
effective strategy to promote quit attempts 
and increase smoking cessation rates is the 
provision of pharmacotherapy at no cost to 
participants.29 Additionally, increasing the 
number of contacts between participants 
and intervention providers may be an effective 
strategy to help those who relapse during 
a quit attempt, and allows continuous 
engagement of smokers on the stage of 
change continuum — precontemplation, 
contemplation, preparation, action, and 
maintenance.30
Implications for research and practice
More than 87% of the Australian population 
visit a GP at least once each year.31 An 
individual makes an average of seven GP 
visits annually.32 Similar statistics have 
been reported in England and Canada.31,32 
Therefore, interventions implemented in this 
setting may present a feasible strategy to 
improving health outcomes at the population 
level through behaviour change interventions 
such as smoking cessation. Although the 
ITT analysis showed no significant difference 
in abstinence rates between the control 
and intervention groups, the results were 
limited by the poor uptake of the intervention, 
especially by those with COPD. 
A pharmacist-coordinated interdisciplinary 
smoking cessation intervention when 
integrated in a general practice setting had 
no advantages over usual care. Further 
research is needed to evaluate the effect 
of home medicines review and home-
based pulmonary rehabilitation on smoking 
abstinence in smokers with COPD.
Funding
The RADICALS trial received funding 
from the National Health and Medical 
Research Council (NHMRC) through 
the NHMRC Partnerships for Better 
Health — Partnership Projects initiative 
(APP1076255). Cash and/or in-kind 
contributions were received from partner 
organisations: Lung Foundation Australia, 
Boehringer Ingelheim Pty Ltd, and Eastern 
Melbourne Primary Health Network (PHN).
Ethical approval
This study was approved by the Monash 
University Human Research Ethics 
Committee (CF14/1018 — 2014000433). 
Provenance
Freely submitted; externally peer reviewed.
Competing interests
Johnson George, Billie Bonevski, and Michael 
J Abramson have held investigator-initiated 
grants from Pfizer and GlaxoSmithKline for 
unrelated research. Michael J Abramson 
has undertaken an unrelated consultancy 
for Sanofi and received assistance for 
conference attendance. Johnson George 
and Nicholas A Zwar are members of 
the Lung Foundation Australia COPD-X 
Guidelines Committee. Anne E Holland is 
a member of the Lung Foundation Australia 
COPD-X: Concise Guide for Primary Care 
Advisory Committee. The remaining authors 
have declared no competing interests.
Acknowledgements
The authors wish to thank the Data Safety 
and Monitoring Board members (Ian Yang, 
Jennifer Alison, and Julia Walters), Denise 
van den Bosch, Jessica Webster, Rita 
Breare, Mieke Hutchinson-Kern, Brigitte 
Borg and The Alfred Respiratory Laboratory, 
Eleonora Del Colle and Pulmetrics staff, 
Brian Meier, Eli Dabscheck, Agape Stratigis, 
Amanda Cross, Amanda Nichols, Andrew 
Clayton, Caroline Nicolson, Francesca Sgroi, 
Georgia Lakoumentas, Hilary Edwards, 
Janet Carberry, Jannette Angell, Kay 
Dunkley, Lisa Austin, Melanie Frodsham, 
Robyn Saunders, Robyn Stell, Ross de Gori, 
Rosemary Moore, Sandy Scholes, Sarah 
Rawlings, Tamara Ford, Yamuna Prashanth, 
and RADICALS clinic staff and participants.
Open access




Contribute and read comments about this 
article: bjgp.org/letters
British Journal of General Practice, June 2021  e463
REFERENCES
1. Australian Commission on Safety and Quality in Health Care. The second 
Australian atlas of healthcare variation. Sydney: ACSQHC, 2017. https://
www.safetyandquality.gov.au/our-work/healthcare-variation/atlas-2017 
(accessed 23 Apr 2021).
2. Australian Government. Australian Institute of Health and Welfare. Chronic 
obstructive pulmonary disease (COPD). Canberra: AIHW, 2020. https://www.
aihw.gov.au/reports/chronic-respiratory-conditions/copd/contents/copd 
(accessed 23 Apr 2021).
3. Zwar NA, Richmond RL, Halcomb EJ, et al. Quit in general practice: a cluster 
randomised trial of enhanced in-practice support for smoking cessation. Fam 
Pract 2015; 32(2): 173–180. 
4. Harris MF, Fanaian M, Jayasinghe UW, et al. What predicts patient-reported GP 
management of smoking, nutrition, alcohol, physical activity and weight? Aust J 
Prim Health 2012; 18(2): 123–128. 
5. Young JM, Ward JE. Implementing guidelines for smoking cessation advice in 
Australian general practice: opinions, current practices, readiness to change 
and perceived barriers. Fam Pract 2001; 18(1): 14–20: 
6. Carson–Chahhoud KV, Livingstone–Banks J, Sharrad KJ, et al. Community 
pharmacy personnel interventions for smoking cessation. Cochrane Database 
Syst Rev 2019; (10): CD003698. 
7. Liang J, Abramson MJ, Zwar N, et al. Interdisciplinary model of care 
(RADICALS) for early detection and management of chronic obstructive 
pulmonary disease (COPD) in Australian primary care: study protocol for a 
cluster randomised controlled trial. BMJ Open 2017; 7(9): e016985. 
8. Liang J, Abramson MJ, Russell G, et al. Interdisciplinary COPD intervention in 
primary care: a cluster randomised controlled trial. Eur Respir J 2019; 53(4): 
1801530. 
9. Liang J, Abramson MJ, Zwar NA, et al. Diagnosing COPD and supporting 
smoking cessation in general practice: evidence–practice gaps. Med J Aust 
2018; 208(1): 29–34. 
10. Royal Australian College of General Practitioners. Supporting smoking 
cessation: A guide for health professionals. 2nd edn. East Melbourne, Victoria: 
RACGP, 2020. https://www.racgp.org.au/clinical-resources/clinical-guidelines/
key-racgp-guidelines/view-all-racgp-guidelines/supporting-smoking-cessation 
(accessed 23 Apr 2021).
11. Quitline resource centre. Quit education. 2021. https://www.quit.org.au/
resources/quit-education/ (accessed 23 Apr 2021).
12. Thomas D, Abramson MJ, Bonevski B, et al. A pharmacist-led system-change 
smoking cessation intervention for smokers admitted to Australian public 
hospitals (GIVE UP FOR GOOD): study protocol for a randomised controlled trial. 
Trials 2013; 14: 148. 
13. Thomas D, Abramson MJ, Bonevski B, et al. Integrating smoking cessation 
into routine care in hospitals — a randomised controlled trial. Addiction 2016; 
111(4): 714–723. 
14. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using 
minimal resources: a randomised, controlled equivalence trial. Thorax 2017; 
72(1): 57–65. 
15. SRNT Subcommittee on Biochemical Verification. Biochemical verification of 
tobacco use and cessation. Nicotine Tob Res 2002; 4(2): 149–159.
16. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation 
trials: proposal for a common standard. Addiction 2005; 100(3): 299–303. 
17. Miller C, Wakefield M, Roberts L. Uptake and effectiveness of the Australian 
telephone Quitline service in the context of a mass media campaign. Tob 
Control 2003; 12(Suppl 2): ii53–ii58. 
18. Coleman T, Wilson A. Anti-smoking advice in general practice consultations: 
general practitioners’ attitudes, reported practice and perceived problems. Br J 
Gen Pract 1996; 46(403): 87–91.
19. Chen J, Chen Y, Chen P, et al. Effectiveness of individual counseling for 
smoking cessation in smokers with chronic obstructive pulmonary disease and 
asymptomatic smokers. Exp Ther Med 2014; 7(3): 716–720. 
20. Zwar NA, Bunker JM, Reddel HK, et al. Early intervention for chronic 
obstructive pulmonary disease by practice nurse and GP teams: a cluster 
randomised trial. Fam Pract 2016; 33(6): 663–670. 
21. Vuong K, Hermiz O, Razee H, et al. The experiences of smoking cessation 
among patients with chronic obstructive pulmonary disease in Australian 
general practice: a qualitative descriptive study. Fam Pract 2016; 33(6): 715–
720. 
22. Coups EJ, Dhingra LK, Heckman CJ, Manne SL. Receipt of provider advice for 
smoking cessation and use of smoking cessation treatments among cancer 
survivors. J Gen Intern Med 2009; 24(Suppl 2): S480–S486. 
23. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation 
treatments in the United States. Am J Prev Med 2008; 34(2): 102–111. 
24. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions 
for smoking cessation: an overview and network meta–analysis. Cochrane 
Database Syst Rev 2013; (5): CD009329. 
25. Cahill K, Lindson–Hawley N, Thomas KH, et al. Nicotine receptor partial 
agonists for smoking cessation. Cochrane Database Syst Rev 2016; (5): 
CD006103. 
26. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking 
cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179(2): 
135–144.
27. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term 
abstinence among untreated smokers. Addiction 2004; 99(1): 29–38. 
28. Lancaster T, Stead LF. Individual behavioural counselling for smoking 
cessation. Cochrane Database Syst Rev 2017; (3): CD001292. 
29. Tinkelman D, Wilson SM, Willett J, Sweeney CT. Offering free NRT through 
a tobacco quitline: impact on utilisation and quit rates. Tob Control 2007; 
16(Suppl 1): i42–i46. 
30. Pbert L, Jolicoeur D, Hayes R, Ockene JK. Addressing tobacco use and 
dependence. In: Riekert KA, Ockene JK, Pbert L, eds. The handbook of health 
behavior change. 4th edn. New York: Springer Publishing Company, 2013: 
179–209.
31. Royal Australian College of General Practitioners. General practice: health 
of the nation 2018. An annual insight into the state of general practice. 
East Melbourne, Victoria: RACGP, 2018. https://www.racgp.org.au/
download/Documents/Publications/Health-of-the-Nation-2018-Report.pdf 
(accessed 23 Apr 2021).
31. McCarthy N. Americans Visit Their Doctor 4 Times A Year. People In Japan Visit 
13 Times A Year [infographic], (Source: Commonwealth Fund). Forbes 2014; 
4 Sep: https://www.forbes.com/sites/niallmccarthy/2014/09/04/americans-
visit-their-doctor-4-times-a-year-people-in-japan-visit-13-times-a-year-
infographic/ (accessed 23 Apr 2021).
32. The Commonwealth Fund. Average annual number of physician 
visits per capita. 2017. New York: Commonwealth Fund. https://www.
commonwealthfund.org/international-health-policy-center/system-stats/
annual-physician-visits (accessed 23 Apr 2021).
e464  British Journal of General Practice, June 2021
